Details of the distribution of viruses detected in sentinel-source specimens can be found in the Primary care data section.
For week 14/2021, 11 of 30 998 non-sentinel specimens (from sources such as hospitals, schools, primary care facilities not involved in sentinel surveillance, or nursing homes and other institutions) tested positive for an influenza virus: 8 were type A and 3 were type B (Table 2).
Since the beginning of the season, 779 of 646 359 non-sentinel specimens tested positive for influenza viruses; 387 (49.7%) were type A and 392 (50.3%) type B. Of 70 subtyped A viruses, 29 (41.4%) were A(H1)pdm09 and 41 (58.6%) were A(H3). Of 392 type B viruses, only 14 were ascribed to a lineage: 11 B/Victoria and 3 B/Yamagata.
Since week 40/2020, 11 viruses have been characterized genetically:
- 5 type A: 4 influenza A(H3) with 2 attributed to the HA subgroup 3C.2a1b + T131K-A, represented by A/Slovenia/1637/2020, 1 attributed to the HA subgroup 3C.2a1b + T135K-A, represented by A/Denmark/3264/2019 and 1 attributed to the HA subgroup 3C.2a1b+T135K-B represented by A/Hong Kong/2671/2019; and 1 A(H1)pdm09 attributed to the group 6B.1A5A + 187V/A represented by A/Guangdong-Maonan/SWL1536/2019.
- 6 type B: 2 B(Vic)-lineage clade 1A(Δ3)B represented by B/Washington/02/2019 and 4 B(Vic) that were not assigned to any clade.
ECDC published the February virus characterisation report that describes the available data from circulating viruses collected after 31 August 2020.
This and previously published influenza virus characterization reports are available on the ECDC website.
Since the beginning of the season, 4 influenza viruses have been tested for susceptibility to neuraminidase inhibitors: 2 influenza A(H3) viruses and 2 influenza B/Victoria viruses for which sequence analysis indicated normal inhibition by both oseltamivir and zanamivir.